Brain-computer interfaces are arriving faster than the ethical frameworks meant to govern them. Science Corporation, the neurotechnology company founded by former Neuralink president Max Hodak, has published a set of principles intended to establish baseline rights for anyone who might one day have a device wired into their nervous system.
The principles, released by the company in 2024, articulate positions on privacy, offline functionality, ownership, and what Science calls "patient agency." The document functions less as a technical specification and more as a philosophical stake in the ground: what should people with implants be able to expect from the companies building this technology?
The Core Framework
Science's argument begins with a blunt premise: patients must have maximum insight into and control over the inputs, processes, and outputs of devices directly connected to their minds. That sounds obvious. But the consumer technology industry has spent two decades normalizing opaque data flows, compulsory connectivity, and licensing agreements that treat ownership as negotiable.
The company explicitly rejects these practices. Neural interfaces, in Science's view, should never subject users to unwanted surveillance or unexplained monetization. The company's principles document imagines a dystopian scenario where a patient might be prompted to watch an advertisement before their implant functions normally. That example may sound absurd, but it is precisely the business model that has come to define much of the software industry.
Science also insists that core device functionality must work without a network connection. This is a design constraint that runs counter to the industry trend toward always-online devices. But the company argues this is non-negotiable: if the network fails, or the company disappears, or a security breach occurs, a patient's ability to see, communicate, or control their body should not vanish with it.
Ownership and Legal Protection
The principles extend into territory that regulators have barely begun to map. Science's position is that neural data should not be used against patients in legal proceedings, investigations, or other contexts where access to a person's cognitive signals could be weaponized. As interfaces become more sophisticated, the line between patient and device grows blurry. A person's BCI, in a real sense, becomes part of their mind. The company argues that this integration demands new legal protections.
The document also addresses a trend that has eroded property rights across consumer technology: the shift from ownership to licensing. Subscriptions and recurring fees have replaced outright purchase in domains from software to farm equipment. Science's view is that medical devices wired into the brain cannot follow this path. Patients should own their devices outright, not rent them.
Why This Matters Now
Science is not the only company pushing BCIs toward clinical reality. NVIDIA's investments in AI hardware are accelerating signal processing capabilities, and competitors like Neuralink and Synchron are advancing their own human trials. The regulatory landscape remains fragmented: some U.S. states, including Colorado and California, have begun incorporating neural data into privacy laws, but comprehensive federal standards do not exist.
Science itself is preparing to place its first sensor in a human brain, a 520-electrode device that rests on the cortical surface rather than penetrating brain tissue. Dr. Murat Günel, chair of Yale Medical School's Department of Neurosurgery, has signed on to lead the trials. The company has also advanced its PRIMA retinal implant through clinical studies, with preliminary results showing restored reading ability in patients with geographic atrophy.
The broader BCI industry is expected to see commercial approvals for narrowly defined indications, such as severe paralysis with communication impairment, by 2027 or 2028. Wider clinical adoption could follow by 2030. As with other infrastructure-intensive technologies, the pace of deployment will depend on reimbursement pathways, regulatory clarity, and manufacturing scale.
The Human Validation Question
Beyond clinical restoration, BCIs offer something less tangible but potentially more significant: a form of human validation. For patients with severe paralysis, locked-in syndrome, or sensory loss, these devices represent not just restored function but renewed agency. The ability to communicate, to control one's environment, to interact with the world on one's own terms, these are the foundations of autonomous selfhood.
Science's framework centers this explicitly. The company states that patients using its devices should have agency over their lives. That phrasing is careful. Agency is not merely capability. It is the recognition that a person's intentions matter, that their desires for treatment and broader life goals deserve respect.
Research has shown that BCI-mediated actions can affect users' sense of responsibility and self-attribution differently than ordinary bodily movements. As agentic systems proliferate across technology, the question of who or what is acting becomes increasingly complex. For BCIs, the answer must be the patient.
The commercial BCI market is projected to exceed $25 billion by 2034, according to GlobalData analysis. Morgan Stanley estimates an early total addressable market of $80 billion across certain U.S. patient populations. Those numbers will attract companies with varying commitments to patient rights.
Science's principles document is not legally binding. It is a statement of intent from one company in a rapidly expanding field. Whether it shapes industry norms or remains an outlier will depend on how regulators, competitors, and patients respond. The technology is coming. The governance is still being written.
